Universal reference book for medicines

Active substance: cetylpyridinium chloride, lidocaine

Type: The drug with antimicrobial and local anesthetic action for topical application in ENT practice and dentistry

Manufacturer: NOVARTIS CONSUMER HEALTH (Switzerland) manufactured by NOVARTIS URUNLERI (Turkey)
Composition, form of production and packaging
The tablets for resorption (menthol) are white, rectangular, with bevelled edges, with a smell of menthol.
1 tab.

cetylpyridinium chloride 2 mg

lidocaine hydrochloride 1 mg

[PRING] peppermint leaf oil - 0.5 mg, peppermint leaf oil Schimmel - 0.5 mg, levomentol - 6 mg, potassium acesulfame - 6 mg, corn starch - 55 mg, citric acid monohydrate - 5 mg, macrogol 6000 - 25 mg , microcrystalline cellulose (Avicel PH-105) - 20 mg, magnesium stearate - 2 mg, sorbitol (Karion 3140) - 1107 mg.

10 pieces.
- blisters (2) - packs of cardboard.

Description of the drug approved by the manufacturer for the printed edition of 2014.


Combined for topical use, contains antiseptic and local anesthetic.

Cetylpyridinium chloride is an antiseptic from the group of quaternary ammonium compounds, it has bactericidal activity against Gram-positive and to a lesser extent Gram-negative bacteria.
It changes the permeability of the cytoplasmic membrane of bacteria, disrupts the internal oxidative mechanisms of respiration of bacteria, which leads to their death. Cetylpyridinium chloride has antifungal and antiviral activity against enveloped viruses.
Lidocaine hydrochloride is a local anesthetic from the group of amides, and in inflammatory processes it relieves pain in the throat when swallowing.
Lidocaine disrupts the permeability of the cell membrane for sodium ions, which leads to anesthesia as a result of blockade of nerve impulses.

Cetylpyridinium chloride is practically not absorbed through the mucosa of the oral cavity.

Lidocaine hydrochloride is poorly absorbed through the mucous membrane of the oral cavity.
When ingested, it is absorbed, undergoing a metabolism during the "first passage" through the liver. When administered orally, its bioavailability is about 35%. Metabolites are excreted together with urine, less than 10% of the substance is excreted unchanged.

Infectious and inflammatory diseases of the mouth and throat:


- laryngitis;

- Catarrhal angina;

- stomatitis;

ulcerative gingivitis;

- tonsillitis (as an aid).


The tablet should be slowly resorbed in the mouth.

The tablet should not be chewed or swallowed.
Do not take Teraflu В® LAR Menthol during or immediately before meals.
Adults and children over 12 years: 1 tab.
every 1-2 hours with acute inflammation and severe pain. At an easier status - on 1 tab. every 2-3 hours. The maximum daily dose is no more than 6 tablets.
Children from 6 to 12 years: 1 tab.
every 3-4 hours as needed, the maximum daily dose - no more than 3 tab.
Do not use TeraFlu В® LAR Menthol tablets for more than 5 consecutive days.
If symptoms persist or are accompanied by fever, dizziness, or vomiting, stop taking the medication and consult a doctor.

Determination of the frequency of adverse reactions: very often (? 10%);
often (? 1%, but? 10%), infrequently (? 0.1%, but? 1%), rarely (≥0.01%, ≥ 0.1%), very rarely (≥0.01%).
From the digestive system: rarely - nausea;
very rarely diarrhea.
From the skin and subcutaneous tissues: very rarely - skin rash, itching.

Local reactions: rarely - local irritation of the mucous membrane of the mouth and throat.


- I trimester of pregnancy;

- the period of breastfeeding;

- children's age till 6 years;

- deficiency of sugar / isomaltase, intolerance to fructose, glucose-galactose malabsorption;

- Hypersensitivity to the components of the drug.

With caution: open wounds of the oral mucosa.


Contraindicated the use of Teraflu В® LAR Menthol in the first trimester of pregnancy, as the drug penetrates the placental barrier.
Application in the II-III trimesters of pregnancy is possible under the supervision of a doctor, in the event that the expected benefit for the mother exceeds the potential risk to the fetus.
The drug is excreted in breast milk, so it is not recommended to use it during breastfeeding.


Contraindicated in children under the age of 6 years .


The drug should not be taken immediately before meals and at the same time as milk.
Simultaneous intake of the drug with milk and food can reduce local antiseptic and anesthetic effects.
Alcohol increases the absorption of cetylpyridinium chloride, so you should avoid drinking alcohol when taking the drug.

Cetylpyridinium chloride slows the healing of wounds.

In 1 tablet of the drug contains 1107 mg of sorbitol as a sweetener, therefore Teraflu В® LAR Menthol should not be taken to patients with congenital intolerance to fructose.

Impact on the ability to drive vehicles and manage mechanisms

Does not affect.


Symptoms: when you accidentally take the drug (as well as other ammonium compounds) in high doses, nausea and vomiting are possible.
The content of lidocaine in the preparation is insignificant and can not cause serious symptoms of an overdose.
Treatment: stop taking the drug immediately;
it is recommended to drink milk or eat egg whites, whipped in water.

Drug interaction of the drug Teraflu В® LAR Menthol was not revealed.


The drug is approved for use as a means of OTC.


The drug should be stored out of reach of children at a temperature of no higher than 30 В° C.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!